FindTrial
Sign In

The influence of probiotics and Zinc on the patients with non-alcoholic fatty liver disease

The influence of probiotics and Zinc on the serum levels of liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017080135408N1
Enrollment
128
Registered
2017-08-12
Start date
2016-12-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. K76.0

Interventions

Intervention 1: Two protexin probiotic capsules 600 mg (Probiotics international, United Kingdom) and two zinc sulfate capsules 25 mg (Alhavi, Iran)are used daily, at noon and at night after meals, fo
Treatment - Drugs
Treatment - Other
Placebo
Two protexin probiotic capsules 600 mg (Probiotics international, United Kingdom) and two zinc sulfate capsules 25 mg (Alhavi, Iran)are used daily, at noon and at night after meals, for three months.
Two protexin probiotic capsules 600 mg (Probiotics international, United Kingdom) and two zinc placebo capsules are used daily, at noon and at night after meals, for three months. The protexin ca
Two capsules of probiotic placebo and two zinc sulfate capsules 25 mg (Alhavi, Iran) are used daily, at noon and at night after meals, for three months.
Two probiotic placebo capsules and two zinc placebo capsules are used daily, at noon and at night after meals, for three months.

Sponsors

Research Center for Infectious Diseases of the Digestive System, Vice Chancellor research of Ahvaz J
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with non-alcoholic fatty liver disease Exclusion criteria: autoimmune hepatitis- viral hepatitis- liver metabolic diseases- liver metabolic disease- drugs and toxins inception- age below 18- History of receiving medication for NAFLD- History of kidney or heart disease- Taking amiodarone, methotrexate, tamoxifen, glucocorticoids, sodium valproate and anti HIV drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
ALT. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;AST. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;FBS. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;Total cholesterol. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;Triglyceride. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;HDL. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;LDL. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.;CRP. Timepoint: Before and 3 months after intervention. Method of measurement: Blood test.—

Secondary

MeasureTime frame
Weight. Timepoint: Before and 3 months after intervention. Method of measurement: Scale.;Body mass index (BMI). Timepoint: Before and 3 months after intervention. Method of measurement: Body mass is expressed in units of kg/m2.;Waist. Timepoint: Before and 3 months after intervention. Method of measurement: Centimeter.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoumeh Khedri

Ahvaz Jundishapur University of Medical Sciences

khedri.m@ajums.ac.ir+98 61 3221 6104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026